Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
80,91 USD | -1,53% | -8,71% | -16,09% |
26/04 | BIOMARIN PHARMACEUTICAL INC. : Scotiabank mantiene la raccomandazione Neutral | ZM |
25/04 | BIOMARIN PHARMACEUTICAL INC. : prospettiva positiva di Wells Fargo Securities | ZM |
Attività
Numero di dipendenti: 3 401
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Innovative Therapies
100,0
%
| 2 096 | 100,0 % | 2 419 | 100,0 % | +15,42% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
31,9
%
| 684 | 32,6 % | 771 | 31,9 % | +12,72% |
Europe
27,7
%
| 651 | 31,1 % | 669 | 27,7 % | +2,82% |
Rest of World
19,4
%
| 312 | 14,9 % | 468 | 19,4 % | +50,28% |
Latin America
13,7
%
| 267 | 12,7 % | 332 | 13,7 % | +24,60% |
Global
7,4
%
| 182 | 8,7 % | 178 | 7,4 % | -2,47% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Alexander Hardy
CEO | Chief Executive Officer | 56 | 01/12 |
Brian Mueller
DFI | Director of Finance/CFO | 50 | 01/12/02 |
Kevin Eggan
CTO | Chief Tech/Sci/R&D Officer | - | 05/10/20 |
Philip Lo Scalzo
CMP | Compliance Officer | - | 01/01/07 |
Chief Tech/Sci/R&D Officer | - | 01/11/08 | |
C. Guyer
CTO | Chief Tech/Sci/R&D Officer | 62 | - |
Stuart Bunting
CTO | Chief Tech/Sci/R&D Officer | - | 01/11/08 |
Henry Fuchs
CTO | Chief Tech/Sci/R&D Officer | 66 | 01/03/09 |
Director/Board Member | 70 | 16/05/05 | |
Traci McCarty
IRC | Investor Relations Contact | - | - |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 04/01/16 |
Director/Board Member | 70 | 16/05/05 | |
Randy Meier
CHM | Chairman | 65 | 14/12/06 |
Elaine Heron
BRD | Director/Board Member | 76 | 01/07/02 |
V. Lawlis
BRD | Director/Board Member | 72 | 01/06/07 |
May Kin Ho
BRD | Director/Board Member | 71 | 17/02/21 |
Mark Enyedy
BRD | Director/Board Member | 60 | 27/12 |
Robert Hombach
BRD | Director/Board Member | 58 | 29/09/17 |
Willard Dere
BRD | Director/Board Member | 70 | 18/07/16 |
Director/Board Member | 66 | 10/07/19 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 189 776 577 | 188 179 486 ( 99,16 %) | 0 | 99,16 % |
Coordinate società
BioMarin Pharmaceutical, Inc.
770 Lindaro Street
94901, San Rafael
+415 506 6700
http://www.biomarin.comSocietà del gruppo
Nome | Categoria e settore |
---|---|
BioMarin International Ltd.
BioMarin International Ltd. BiotechnologyHealth Technology BioMarin International develops and commercializes biopharmaceuticals. The company was founded on June 16, 2011 and is headquartered in Dublin, Ireland. |
Biotechnology
|
Settore
Vendite per regione
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
-16,09% | 15,36 Mrd | |
-4,66% | 86,13 Mrd | |
+1,32% | 39,82 Mrd | |
-19,27% | 30,42 Mrd | |
+57,86% | 25,23 Mrd | |
-9,14% | 11,95 Mrd | |
-17,69% | 11,6 Mrd | |
-43,00% | 11,51 Mrd | |
+5,24% | 8,71 Mrd | |
-8,42% | 8,12 Mrd |
- Borsa valori
- Azioni
- Azione BMRN
- Società BioMarin Pharmaceutical Inc.